. Author manuscript; available in PMC: 2009 Jun 30.

Published in final edited form as: J Infect Dis. 2009 May 1;199(9):1301–1309. doi: 10.1086/597759

Table 3.

Nevirapine (Nvp) resistance mutations detected in HIV from the latent reservoir and/or plasma of persons from Uganda or South Africa >6 months after receipt of single-dose nevirapine.

						HIV with Nvp resistance mutations
Patient	Study site	HIV subtype	Interval between single-dose Nvp and sampling, months	CD4⁺ cell count, cells/mm³	HIV-1 RNA load, copies/mL	Detected in plasma	Detected in latent reservoir	Identified in plasma before current study
LT1003	Uganda	D	37.5	336	129,546	None	G190A	Not determined
LT1020	Uganda	D	23.2	309	244,545	K103N	K103N, G190A	Not determined
LT2009	South Africa	C	15.3	286	219,064	None	K103N	K103N
LT2028	South Africa	D	32.0	205	14,280	None	K103N	K103N
LT2049	South Africa	C	25.6	291	32,339	K103N	None	None